Does Rallies show 13F holders for VCYT?

Yes. Rallies tracks hedge fund and 13F ownership data for VCYT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VCYT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VCYT. It does not provide personalized investment advice.

VCYT (Veracyte, Inc.) Stock Analysis - Hedge Fund Holdings

Veracyte, Inc. (VCYT) is a publicly traded Healthcare sector company. As of May 21, 2026, VCYT trades at $45.00 with a market cap of $3.31B and a P/E ratio of 40.34. VCYT moved +8.37% today. Year to date, VCYT is +3.58%; over the trailing twelve months it is +56.86%. Its 52-week range spans $22.61 to $50.71. Analyst consensus is buy with an average price target of $45.28. Rallies surfaces VCYT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VCYT stock?

Hedge funds tracked by Rallies that own VCYT include Duquesne Family, Panagora Asset, Bridgewater Associates, Farallon Capital, and Pinebridge Investments. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Veracyte, Inc..

VCYT Key Metrics

Key financial metrics for VCYT
Metric	Value
Price	$45.00
Market Cap	$3.31B
P/E Ratio	40.34
EPS	$1.11
Dividend Yield	0.00%
52-Week High	$50.71
52-Week Low	$22.61
Volume	111
Avg Volume	0
Revenue (TTM)	$541.74M
Net Income	$88.01M
Gross Margin	70.92%

Top Hedge Funds Holding VCYT

Duquesne Family holds 259.94K shares of VCYT, changed +0.00% as of Jun 30, 2024.
Panagora Asset holds 93.94K shares of VCYT, changed -28.67% as of Mar 31, 2026.
Bridgewater Associates holds 91.59K shares of VCYT, changed +222.57% as of Mar 31, 2026.
Farallon Capital holds 7.00K shares of VCYT, changed +0.00% as of Mar 31, 2026.
Pinebridge Investments holds 816 shares of VCYT, changed +0.00% as of Jun 30, 2023.

Latest VCYT News

Veracyte Q1 EPS $0.52 on $139.1M Revenue Beats Forecast, Raises Guidance — May 5, 2026
Veracyte Q4 EPS Jumps 47%, Revenue Up 18.5%, Shares Rally — Feb 26, 2026
Veracyte Posts Over 20% Q4 Revenue Increase, Outlines Diagnostics Expansion — Feb 26, 2026
Veracyte Q4 EPS Beats by 30%, Revenues Rise 18.5% to $140.6M — Feb 26, 2026
Becton Dickinson Unveils Three-Tube Urine Cup Kit to Expand Diagnostics — Feb 24, 2026

Recent VCYT Insider Trades

McGuire Annie sold 5.10K (~$194.13K) on May 6, 2026.
McGuire Annie sold 5.10K (~$204.08K) on May 6, 2026.
Chambers Rebecca sold 4.40K (~$156.41K) on Mar 4, 2026.

VCYT Analyst Consensus

8 analysts cover VCYT: 0 strong buy, 6 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $45.28.

Common questions about VCYT

Who owns VCYT stock?: Hedge funds tracked by Rallies that own VCYT include Duquesne Family, Panagora Asset, Bridgewater Associates, Farallon Capital, and Pinebridge Investments. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Veracyte, Inc..
Does Rallies show 13F holders for VCYT?: Yes. Rallies tracks hedge fund and 13F ownership data for VCYT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VCYT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VCYT. It does not provide personalized investment advice.